Sugi Predict

Sugi Predict / Compounds / SCHEMBL21361644

SCHEMBL21361644

SCHEMBL21361644

C=C1CN(S(=O)(=O)c2ccc(C)cc2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)N2CCCCC2)C1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CD4 P01730 14/20 0.58
▸ SORT1 Q99523 1/20 0.58
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.46
▸ PKM P14618 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ TSHR P16473 1/20 0.43
▸ RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13925179 0.95 CD4 (0.64) CD4SORT1MEN1KMT2ASMN1; SMN2
SCHEMBL21361626 0.91 CD4 (0.59) CD4SORT1MEN1KMT2ASMN1; SMN2
SCHEMBL13925186 0.90 CD4 (0.66) CD4SORT1ALDH1A1PKMPOLB
SCHEMBL23102095 0.90 CD4 (0.58) CD4SORT1MEN1KMT2ASMN1; SMN2
SCHEMBL21361494 0.89 CD4 (0.46) CD4SORT1MEN1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL21359286 0.88 CD4 (0.48) CD4SORT1MEN1KMT2ASMN1; SMN2
SCHEMBL23102158 0.88 CD4 (0.56) CD4SORT1SMN1; SMN2ALDH1A1PKM
SCHEMBL23102072 0.88 CD4 (0.56) CD4SORT1MEN1KMT2ASMN1; SMN2
SCHEMBL21361630 0.88 CD4 (0.56) CD4SORT1ALDH1A1PKMHTT
SCHEMBL21361518 0.86 CD4 (0.54) CD4SORT1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 — — EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 — — US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 — — US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 — — US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CD4 3678/4885SORT1 2452/4885MEN1 2214/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3727/4885SORT1 2562/4885MEN1 2318/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3471/4885SORT1 2267/4885MEN1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.